Patent intelligence · WO
WO 2006031885
PEPTIDES DE LIAISON A LA REGION DU DOMAINE KINASE (KDR) ET AU COMPLEXE FACTEUR DE CROISSANCE ENDOTHELIALE VASCULAIRE/REGION DU DOMAINE KINASE (VEGF/KDR)
PEPTIDES DE LIAISON A LA REGION DU DOMAINE KINASE (KDR) ET AU COMPLEXE FACTEUR DE CROISSANCE ENDOTHELIALE VASCULAIRE/REGION DU DOMAINE KINAS…
Patent details — WO 2006031885
- Jurisdiction
- WO
- Status
- expired
- Grant date
- Mar 23, 2006
- Expiration
- Mar 18, 2026
- Applicant
- DYAX CORP [US]
- CPC classes
- A61K 38/ 10 A I
Quick answer
WO 2006031885 (PEPTIDES DE LIAISON A LA REGION DU DOMAINE KINASE (KDR) ET AU COMPLEXE FACTEUR DE CROISSANCE ENDOTHELIALE VASCULAIRE/REGION DU DOMAINE KINASE (VEGF/KDR)) is held by DYAX CORP [US]. Status: expired. Granted Mar 23, 2006. Expires Mar 18, 2026 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- DYAX CORP [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 38/ 10 A I
More from DYAX CORP [US]
Related pharmaceutical patents in our USPTO index.
-
IL 172160
Method for non-invasive quantification of perfusion in a tissue
granted -
EP 2117603
TARGETING UND THERAPEUTISCHE VERBINDUNGEN UND GASGEFÜLLTE MIKROVESIKEL MIT DIESEN VERBINDUNGEN
granted -
WO 2009076388
CONJUGUÉS VECTEUR DE CIBLAGE - PHOSPHOLIPIDE
granted -
CA 2670932
DETECTION DU DETACHEMENT D'UN AGENT DE CONTRASTE IMMOBILISE DANS DES APPLICATIONS D'IMAGERIE MEDICALE
granted -
US 2008107607
TARGETING VECTOR-PHOSPHOLIPID CONJUGATES
granted -
US 2008063603
ULTRASOUND CONTRAST AGENTS AND METHODS OF MAKING AND USING THEM
granted -
CA 2631716
CONJUGUES VECTEUR DE CIBLAGE-PHOSPHOLIPIDES
granted -
US 2007128117
Ultrasound contrast agents and process for the preparation thereof
granted
Frequently asked questions
What is US patent 2006031885?
WO 2006031885 (PEPTIDES DE LIAISON A LA REGION DU DOMAINE KINASE (KDR) ET AU COMPLEXE FACTEUR DE CROISSANCE ENDOTHELIALE VASCULAIRE/REGION DU DOMAINE KINASE (VEGF/KDR)) is held by DYAX CORP [US]. Status: expired. Granted Mar 23, 2006. Expires Mar 18, 2026 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2006031885?
DYAX CORP [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does WO 2006031885 expire?
Our index shows an expiration date of Mar 18, 2026 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.